Royalty Pharma Raises $3.6 Billion to Refinance $2.75 Billion of Outstanding Debt and to Fund an $850 Million Cash Distribution to Shareholders

New York, NY – September 07, 2011 – Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, announced that it has successfully refinanced $2.75 billion of outstanding debt and funded a one-time $850 million cash distribution to shareholders.

Source: Original Article